151 related articles for article (PubMed ID: 17003918)
1. Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects.
Heim HK; Broich K
Thromb Haemost; 2006 Oct; 96(4):423-32. PubMed ID: 17003918
[TBL] [Abstract][Full Text] [Related]
2. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
3. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
[TBL] [Abstract][Full Text] [Related]
4. Clinical use and pharmacological properties of selective COX-2 inhibitors.
Shi S; Klotz U
Eur J Clin Pharmacol; 2008 Mar; 64(3):233-52. PubMed ID: 17999057
[TBL] [Abstract][Full Text] [Related]
5. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
[TBL] [Abstract][Full Text] [Related]
6. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
Mukherjee D
Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915
[TBL] [Abstract][Full Text] [Related]
7. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Chen LC; Ashcroft DM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):762-72. PubMed ID: 17457957
[TBL] [Abstract][Full Text] [Related]
8. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
Kasliwal R; Layton D; Harris S; Wilton L; Shakir SA
Drug Saf; 2005; 28(9):803-16. PubMed ID: 16119973
[TBL] [Abstract][Full Text] [Related]
9. COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database.
Durrieu G; Olivier P; Montastruc JL;
Eur J Clin Pharmacol; 2005 Sep; 61(8):611-4. PubMed ID: 16133552
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
Andersohn F; Schade R; Suissa S; Garbe E
Stroke; 2006 Jul; 37(7):1725-30. PubMed ID: 16728684
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
McCormack PL
Drugs; 2011 Dec; 71(18):2457-89. PubMed ID: 22141388
[TBL] [Abstract][Full Text] [Related]
12. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35 Suppl 1():25-34. PubMed ID: 17870550
[TBL] [Abstract][Full Text] [Related]
13. Coxibs: can this class of drugs survive?
Tabrizchi R
Vasc Health Risk Manag; 2005; 1(1):5-8. PubMed ID: 17319092
[No Abstract] [Full Text] [Related]
14. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.
Layton D; Marshall V; Boshier A; Friedmann P; Shakir SA
Drug Saf; 2006; 29(8):687-96. PubMed ID: 16872242
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of selective COX-2 inhibitors.
Capone ML; Tacconelli S; Sciulli MG; Patrignani P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
[TBL] [Abstract][Full Text] [Related]
16. COX-2 selective inhibitors and heart health.
Simon LS; White WB
Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
[TBL] [Abstract][Full Text] [Related]
17. Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology.
Clark DW; Layton D; Shakir SA
Drug Saf; 2004; 27(7):427-56. PubMed ID: 15141995
[TBL] [Abstract][Full Text] [Related]
18. [COX-2 inhibitors--one step forward and two steps back].
Evensen S; Spigset O; Slørdal L
Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
[TBL] [Abstract][Full Text] [Related]
19. Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study.
Gudbjornsson B; Thorsteinsson SB; Sigvaldason H; Einarsdottir R; Johannsson M; Zoega H; Halldorsson M; Thorgeirsson G
Eur J Clin Pharmacol; 2010 Jun; 66(6):619-25. PubMed ID: 20157701
[TBL] [Abstract][Full Text] [Related]
20. COX-2 inhibitors and the heart: are all coxibs the same?
Sooriakumaran P
Postgrad Med J; 2006 Apr; 82(966):242-5. PubMed ID: 16597810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
